63
Participants
Start Date
April 30, 2008
Primary Completion Date
October 31, 2008
Study Completion Date
September 30, 2010
nab paclitaxel
100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
Cyclophosphamide
600 mg/m2 of IV cyclophosphamide
Trastuzumab
8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
Center for Cancer and Blood Disorders, Bethesda
Peninsula Cancer Institute, Newport News
Cancer Care of Western North Carolina, Asheville
Gulfcoast Oncology Associates, St. Petersburg
Watson Clinic Center for Cancer Care and Research, Lakeland
Tennessee Oncology, PLLC, Nashville
Consultants in Blood Disorders and Cancer, Louisville
Grand Rapids Clinical Oncology Program, Grand Rapids
St. Louis Cancer Care, Chesterfield
Mercy Hospital, Portland
Collaborators (1)
Celgene Corporation
INDUSTRY
SCRI Development Innovations, LLC
OTHER